OBJECTIVE: To assess whether primary and secondary vestibulodynia represent different pathologic pathways.
METHODS: This was an analysis of archived vestibulectomy specimens from 88 premenopausal women with vestibulodynia (2002–2008). Patient records were reviewed to classify the type of vestibulodynia, duration of symptoms, and hormone status. Histologic sections were stained for hematoxylin and eosin to grade inflammation, S100 to highlight nerves, CD117 for mast cells, estrogen receptor α, and progesterone receptor. Differences between primary and secondary vestibulodynia were tested by t tests, chi-square analysis, and linear and logistic regression.
RESULTS: Primary vestibulodynia showed significant neural hypertrophy and hyperplasia (P=.02, adjusted odds ratio [OR] 3.01, 95% confidence interval [CI] 1.2–7.6) and increased progesterone receptor nuclear immunostaining (P=.004, adjusted OR 3.94, CI 1.6–9.9) compared with secondary vestibulodynia. Estrogen receptor α expression was also greater in primary vestibulodynia when symptom diagnosis was less than 5 years (P=.004, adjusted OR 5.53 CI 1.71–17.91).
CONCLUSION: Primary and secondary vestibulodynia have significantly different histologic features, suggesting that they may have separate mechanistic pathways. Clinically, this may mean the discovery of distinct conditions.
LEVEL OF EVIDENCE: II
Histopathologic differences between primary and secondary vestibulodynia may suggest potentially distinct pathogenic pathways.
From the Departments of Obstetrics and Gynecology, Pathology, and Public Health & Preventative Medicine, Oregon Health & Science University, Portland, Oregon.
Funded by the National Vulvodynia Association. T.K.M.'s contribution was also funded by the Office of Research on Women's Health and the National Institute of Child Health and Human Development, Oregon BIRCWH HD043488-08.
Presented at the 2010 meeting of the Pacific Coast Obstetrical and Gynecological Society, September 29–October 3, 2010, Kona, Hawaii. Portions of these results also were presented at the 2010 meeting of the United States and Canadian Academy of Pathology, March 20–26, 2010, Washington, DC.
Corresponding author: Catherine M. Leclair, MD, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, UHN 50, Portland, OR 97239; e-mail: firstname.lastname@example.org.
Financial Disclosure The authors did not report any potential conflicts of interest.
Vestibulodynia is a localized vulvar pain condition that commonly results in entry dyspareunia.1,2 Although the cause of vestibulodynia remains unclear, histologic evaluation of the vulvar vestibule tissues of affected women has revealed that the skin has more and larger nerves compared with this tissue in unaffected women. Researchers speculate that this change is in part or fully responsible for the manifestation of pain.3–5 Although a lymphocytic infiltrate has been found to occur locally within painful tissue,3–6 a classic inflammatory response has not been found,7–10 and treatments that target the cyclo-oxygenase 2 or nitric oxide systems are likely to be ineffective.11 Mediators of this neuroinflammatory response such as hormonal triggers (estrogen, progestin), infection, and inflammatory factors (mast cells, heparinase) continue to be investigated.6,12–18
In a prospective study of 24 premenopausal women,19 our research team investigated hormonal and histologic markers in those with vestibulodynia compared with those without the condition (control group). Affected women were grouped into two types of vestibulodynia: primary or secondary. Primary sufferers experienced pain at first introital touch, whether with tampon insertion or sexual debut. Women with secondary vestibulodynia experienced pain after an interval of painless intercourse. Similar to previous reports, we found more neural hyperplasia and hypertrophy and inflammation in vestibulodynia specimens compared with negative control biopsies, but we also observed a trend toward more neural hyperplasia and hypertrophy and less chronic inflammation in primary vestibulodynia (n=10) compared with secondary disease (n=10).
Our prior study raised a few questions. First, it suggested the mechanistic pathways in primary and secondary vestibulodynia may be different. Therefore, if we control for disease duration, will primary and secondary vestibulodynia have similar or different histopathology? Second, if they do represent distinct pathways, what insights will histopathology provide? We now present a larger analysis of our archived vestibulectomy specimens to address these questions.
MATERIALS AND METHODS
Using an institutional review board-approved protocol (IRB #3613 Oregon Health & Sciences University), we identified 88 cases of premenopausal vestibulodynia in our Oregon Health & Science University Pathology Database (2002–2008) by matching for diagnosis (vulvar vestibular syndrome, vulvodynia, vestibulodynia) or procedure (vestibulectomy). We searched billing records by procedure code and crosschecked M.G.'s personal database of all vestibulectomy surgeries. Archived tissue specimens were obtained from patients previously seen in the Oregon Health & Sciences University Program in Vulvar Health that met Friedrich criteria for vestibulodynia20 and had severe or moderate dyspareunia. All clinic visits and outpatient vestibulectomies were performed by either C.M.L. or M.F.G. All specimens were obtained from localized vestibulectomies in which the hymen and occasionally 1 cm of distal vagina was used as the surgical flap.21 Patient clinical records were reviewed by C.M.L. and M.F.G. to verify patient age, parity, premenopausal status, primary compared with secondary classification, hormonal status (combined contraceptive steroids and menstrual cycle phase), and duration of symptoms.
Routine paraffin-embedded histologic sections (3–5 micrometers) were stained for hematoxylin and eosin to grade for inflammation. Serial sections were immunostained for S100 (nerves), CD117 (mast cells), presence of progesterone receptor, and presence of estrogen receptor α as we previously described in our prospective study.19 Notably, estrogen receptor β and epidermal nerve twig staining with PGP9.5 were not informative in our prior study19 and were therefore not used in this retrospective analysis. Staining quality and specificity was confirmed by an expert pathologist (T.M.K.) using appropriate controls (eg, nerves for S100 and breast tissue for hormone receptors).
Cases were independently scored by two pathologists (T.K.M. and V.B.K.) who were blinded to clinical and demographic data. Scoring was performed as described in our prior study.19 Briefly, chronic inflammation was scored as none (0), mild (1+), or moderate (2+). S100-positive nuclear immunostaining in nerves was scored as none (0), mild (1+), moderate (2+), or severe (3+) neural hypertrophy or hyperplasia. Estrogen and progesterone receptor nuclear immunostaining were scored similar to routine breast pathology using a 0–3+ scale: 0=negative; 1+=less than 10%; 2+=11–50%; 3+=51–100% of basal cells. CD117-positive mast cells were quantified as the average number of mast cells in the three high-power microscopic fields (40× objective) with the most mast cells in the biopsy. Significant discrepancies between pathologists' scores were settled by joint arbitration and mast cell counts provided by each pathologist for each case were averaged.
Statistical analyses of the data were performed with SAS statistical software. Histology agreement between pathologists is reported with the κ statistic. Comparisons of patient characteristics between primary and secondary vestibulodynia were conducted using chi-square tests for dichotomous variables and t tests with Satterthwaite adjustment for unequal variances for continuous variables.22 Histologic findings were compared by proportional odds logistic regression models and ordinary binary logistic regression.23 The proportional odds logistic regression models take advantage of the ordinal nature of the outcomes and are more powerful than binary logistic regression for a given sample size.24 Linear regression analyses were used to compare mean number of mast cells in primary and secondary vestibulodynia. Age and duration were incorporated into logistic and linear regression models after application of the natural logarithmic transformation (as a result of skewness). We present, separately, results adjusted for age and duration and then results adjusted for age, duration, combined contraceptive steroid use, and parity. In the discussion of results, we focus on the full models that adjust for age, duration, combined contraceptive steroid use, and parity and refer to the associated estimated odds ratios (ORs) (mean differences) as fully adjusted ORs (mean differences). Because the cell sizes were not large, we compared results with models adjusting for confounders one at a time as well as results from models in which the four-category ordinal outcomes were collapsed to two categories.
Forty-two of the 88 cases had primary vestibulodynia (48%) and 46 had secondary (52%). The number of premenopausal women on combined contraceptive steroids was nearly equal in the primary (52%) and secondary (54%) groups. Similar to prior reports,18 patients with primary vestibulodynia were significantly younger (median 26.5 years) than those with secondary vestibulodynia (median 29.5 years, P=.004); the median age of all patients was 28 years. Primary cases tended to be nulliparous compared with women with secondary vestibulodynia (83% compared with 67%, respectively, P=.08) and symptom duration was significantly longer in primary (median 6 years) compared with secondary disease (median 4 years, P=.002).
It is noteworthy that the majority of cases had vestibulodynia for years before having a vestibulectomy. Women reported trying multiple therapies for vestibulodynia before a vestibulectomy. Of the 46 women with secondary vestibulodynia, 57% recalled associations with particular health events; 22% related that the onset of pain was postpartum, 17% recalled that pain began within months (less than 3 months) of treatment for human papilloma virus by loop electrocautery excision procedure or laser, 11% stated pain began after an episode of complicated cystitis, 4% noted an unusually severe vaginitis when pain started, and 2% reported an irritable bowel syndrome flare associated with onset of pain.
We observed good to excellent agreement between pathologists scoring histologic sections for inflammation, neural hypertrophy and hyperplasia, and hormone receptors (κ statistics ranged from 0.63 to greater than 0.8). Similar to our prior prospective study,19 we observed significantly more neural hypertrophy and hyperplasia (Figs. 1 and 2A–B) in primary vestibulodynia compared with secondary vestibulodynia (Table 1). The significant difference persisted even after adjusting for age, parity, combined contraceptive steroid use, and duration of symptoms (fully adjusted OR 3.01, P=.02).
There was no difference in chronic inflammation between primary and secondary cases (unadjusted OR 0.65, P=.31; fully adjusted OR 0.64, P=.37). In addition, none of the potential covariables (age, parity, duration of symptoms, and combined contraceptive steroid use) were associated with the level of inflammation. Mast cell numbers were increased in both types of vestibulodynia (Fig. 1), but there was no difference between primary and secondary (fully adjusted mean difference 0.49, P=.85).
Secondary vestibulodynia showed less progesterone receptor staining than primary disease (Figs. 1 and 2C–D). Progesterone receptor density was significantly greater in primary vestibulodynia by both univariable and multivariable analyses (fully adjusted OR 3.94, P=.004) (Table 1). Examination of multivariable models for estrogen receptor expression suggested potential differences between primary and secondary conditions. In women with symptom recognition less than 5 years, the primary group was more likely (fully adjusted OR 5.53, P=.004) than the secondary group to have more estrogen receptor (Figs. 1 and 2E–F). With longer symptom duration, there was no significant difference in estrogen receptor expression (fully adjusted OR 0.69, P=.59) between primary and secondary disease. When dichotomizing estrogen receptor and progesterone receptor (collapsing the two smallest and two largest categories), we found results that were very similar to those described in Table 1. In particular, for progesterone receptor, which had a marked change from unadjusted to adjusted analyses, the corresponding ORs based on the dichotomous outcome were 2.77 (P=.02), 3.61 (P=.01), and 3.63 (P=.02) for the unadjusted model, the model adjusting for age and duration and the model adjusting for age, duration, combined contraceptive steroid use and parity, respectively. Also, we note that both age and duration appear individually to be negative confounders in the relationship between primary and secondary status and progesterone receptor. When adjusting for age and duration individually, the ORs for progesterone receptor are 3.17 (P=.007) and 3.14 (P=.007), respectively. The similarity of the results from the different adjusted proportional odds models and the similarity of the results from binary logistic regression to those based on using the full set of categories suggest that the results are fairly robust even with the small sample size.
Our data support the hypothesis that primary and secondary vestibulodynia may have distinct histopathologic pathways. Both subtypes showed increased chronic inflammation with mast cell recruitment. However, the primary type showed significant neural hypertrophy and hyperplasia with increased progesterone receptors compared with secondary. These differences persisted even after controlling for disease duration, which suggests that primary and secondary vestibulodynia may develop along different pathogenic pathways rather than representing different stages of the same disease.
Previous studies have demonstrated neural hypertrophy and hyperplasia in vestibulodynia compared with negative controls,3–6 but those smaller studies did not distinguish between primary and secondary vestibulodynia. Our prior prospective analysis found significant differences between these two clinical variants,19 but it too lacked the statistical power to reliably test this hypothesis. For example, in our prior study, we observed more chronic inflammation in secondary vestibulodynia than in primary.19 This larger study does not support that observation, showing equivalent increases of chronic inflammation in both primary and secondary groups. Therefore, chronic lymphocyte infiltrates may be integral to maintaining the pain process in both subtypes,7–10,13,17 and in fact, neurotrophins and inflammatory mediators have been implicated in abnormal nociceptive function.25,26 Moreover, in our prior prospective study, we observed increased chronic inflammation in both the tender and nontender areas of the vestibule, suggesting that the entire vestibule demonstrates hallmarks of an altered process.19 We conclude that the neuroinflammatory relationship in vestibulodynia deserves continued investigation.
Endocrine causation has been implicated in the development of vestibulodynia, and our data revealed hormonal receptor differences between primary and secondary vestibulodynia. Loss of estrogen has been hypothesized as a trigger for some women with vestibulodynia.15,16 Clinically, lack of estrogen provokes vestibulodynia in postpartum and postmenopausal women.27,28 Of our 46 women in the secondary group, 22% developed pain in a postpartum setting, consistent with an earlier descriptive series on vestibulodynia.29
Case–control studies have suggested that oral contraceptive use is associated with vestibulodynia.30–33 This is an important clinical issue as a result of the widespread use of combined contraceptive steroids. Clinically, very few women note variations in their vestibular pain associated with these medicines or the menstrual phase.29 Combined contraceptive steroids are progestin-dominant and although progestins are known to downregulate progesterone receptor,34 this has not been demonstrated in vestibule tissues.33 Also, Johanesson's33 small controlled study evaluating women on and off combined contraceptive steroids noted only minor differences in vestibular estrogen receptor status. Our data, too, did not demonstrate receptor differences in women on combined contraceptive steroids compared with nonusers.
Our study may provide insights into different potential triggers and associations for primary and secondary vestibulodynia, but it does not prove causation. For example, our data suggest that the loss of progesterone receptor is associated with secondary vestibulodynia. Thirty-two percent of secondaries identified infection as a trigger, but how this might relate to progesterone receptor is unclear. The trigger for primary vestibulodynia is not clinically evident because these patients present having had the condition from first penetrative experience, usually many years previously. However, we cannot exclude the role of estrogen in an earlier step in the development of the process. There are no data regarding normal variation of introital tenderness in prepubertal girls and it is possible that childhood tenderness from low estrogen resolves with the pubertal rise in estrogen. If the rise in pubertal estrogen locally fails in a small proportion of young women, we hypothesize that this may lead to a neuroinflammatory response in the vestibular tissue and subsequent vestibulodynia. This remains to be tested.
Finally, it is interesting to consider that vestibulodynia may be similar to interstitial cystitis, another chronic pain condition in a tissue with identical embryonic derivation (endoderm). Both interstitial cystitis and vestibulodynia are histologically characterized by chronic inflammation, increased mast cells, and neural hyperplasia and hypertrophy.35 Indeed, some women have both interstitial cystitis and vestibulodynia.36 Moreover, interstitial cystitis also appears to be related to an imbalance in estrogen receptor and progesterone receptor.37
This large study of 88 archived vestibulectomy specimens demonstrated histopathologic differences between primary and secondary vestibulodynia. Although one strength of this study is its size, heterogeneity was also introduced by this large population. To reduce the heterogeneity, we elected to present only the findings in premenopausal women in this report. Care was taken to gather detailed histories, but it should be noted that assigning a specific duration for primary disease was especially challenging because these women recognized their pain at varying times from the first attempt at tampon use to first attempted coitus later in life. Methodologically, a retrospective study is descriptive and cannot control for factors like the phase of the menstrual cycle or use of combined contraceptive steroids. Our findings could not be compared with control tissues, and indeed the literature on the vulvar vestibule lacks descriptions of normal histology.
In summary, our results suggest primary and secondary vestibulodynia may have distinct pathogenic pathways. A variety of triggers (environmental, hormonal, infectious) may lead to this condition, but future studies aiming to identify and treat these triggers should discriminate between primary and secondary vestibulodynia.
1. Bachmann GA, Rosen R, Pinn VW, Utian WH, Ayers C, Basson R, et al. Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. J Reprod Med 2006;51:447–56.
2. Harlow B, Stewart E. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc 2003;58:82–8.
3. Tympanidis P, Terenghi G, Dowd P. Increased innervation of the vulval vestibule in patients with vulvodynia. Br J Dermatol 2003;148:1021–7.
4. Westrom L, Willen R. Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome. Obstet Gynecol 1998;91:572–6.
5. Bohm-Starke N, Hilleges M, Falconer C, Rylander E. Increased intraepithelial innervation in women with vulvar vestibulitis syndrome. Gynecol Obstet Invest 1998;46:256–60.
6. Pyka RE, Wilkinson EJ, Friedrich EG Jr, Croker B. The histopathology of vulvar vestibulitis syndrome. Int J Gynecol Pathol 1988;7:249–57.
7. Foster DD, Hasday JD. Elevated tissue levels of interleukin-1 beta and tumor necrosis factor-alpha in vulvar vestibulitis. Obstet Gynecol 1997;89:291–6.
8. Gerber S, Bongiovanni A, Ledger W, Witkin S. Defective regulation of the proinflammatory immune response in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol 2002;186:696–700.
9. Gerber S, Bongiovanni A, Ledger W, Witkin S. A deficiency in interferon-alpha production in women with vulvar vestibulitis. Am J Obstet Gynecol 2002;186:361–4.
10. Foster D, Piekarz K, Murant T, LaPoint R, Haidaris C, Phipps R. Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: implications for vulvar vestibulitis. Am J Obstet Gynecol 2007;196:346.e1–8.
11. Bohm-Starke N, Falconer C, Rylander E, Hilliges M. The expression of cyclooxygenase 2 and inducible nitric oxide synthase indicates no active inflammation in vulvar vestibulitis. Acta Obstet Gynecol Scand 2001;80:638–44.
12. Woodruff JD, Parmely TH. Infection of the minor vestibular gland. Obstet Gynecol 1983;62:609–12.
13. Lundquist EN, Hofer PA, Oloffson JI, Sjoberg I. Is vulvar vestibulitis an inflammatory condition? A comparison of histological findings in affected and healthy women. Acta Derm Venereol 1997;77:319–22.
14. Zoubina E, Smith P. Sympathetic hyperinnervation of the uterus in the estrogen receptor alpha knock-out mouse. Neuroscience 2001;103:237–44.
15. Eva L, Maclean A, Reid W, Rolfe K, Perrett C. Estrogen receptor expression in vulvar vestibulitis syndrome. Am J Obstet Gynecol 2003;189:458–61.
16. Johannesson U, Sahlin L, Masironi B, Hilliges M, Blomgren B, Rylander E, et al. Steroid receptor expression and morphology in provoked vestibulodynia. Am J Obstet Gynecol 2008;198:311.e1–6.
17. Bornstein J, Cohen Y, Zarfati D, Sela S, Ophir E. Involvement of heparinase in the pathogenesis of localized vulvodynia. Intl J Gynecol Pathol 2008;27:136–41.
18. Bornstein J, Maman M, Abramovici H. ‘Primary' versus ‘secondary' vulvar vestibulitis: one disease, two variants. Am J Obstet Gynecol 2001;184:28–31.
19. Goetsch M, Morgan T, Korcheva V, Li H, Peters D, Leclair C. Histologic and receptor analysis of primary and secondary vestibulodynia and controls: a prospective study. Am J Obstet Gynecol 2010;202:614.e1–8.
20. Friedrich EG Jr. Vulvar vestibulitis syndrome. J Repro Med 1987;32:110.
21. Goetsch MF. Simplified surgical revision of the vulvar vestibule for vulvar vestibulitis. Am J Obstet Gynecol 1996;174:1701–5; discussion 1705–7.
22. Satterthwaite FE. An approximate distribution of estimates of variance components. Biometrics 1946;2:110–4.
23. Hosmer DW, Lemeshow S. Applied logistic regression. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons, Inc; 2000.
24. Whitehead J. Sample size calculations for ordered categorical data. Stat Med 1993;12:2257–71. Erratum in Stat Med 1994;13:871.
25. Theodosiou M, Rush R, Zhou X, Hu D, Walker J, Tracey D. Hyperalgesia due to nerve damage: role of nerve growth factor. Pain 1999;81:245–55.
26. Shu X, Mendell L. Neurotrophins and hyperalgesia. Proc Natl Acad Sci U S A 1999;96:7693–6.
27. Goetsch MF. Postpartum dyspareunia. An unexplored problem. J Reprod Med 1999;44:963–8.
28. Bachman G, Rosen R. Vulvodynia and menopause. Menopause Management 2006;March/April:14–21.
29. Goetsch MF. Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. Am J Obstet Gynecol 1991;164:1609–14; discussion 1614–6.
30. Bazin S, Bouchard C, Brisson J, Morin C, Meisels A, Fortier M. Vulvar vestibulitis syndrome: an exploratory case–control study. Obstet Gynecol 1994;83:47–50.
31. Bouchard C, Brisson J, Fortier M, Morin C, Blanchette C. Use of oral contraceptive pills and vulvar vestibulitis: a case–control study. Am J Epidemiol 2002;156: 254–61.
32. Sjoberg I, Nylander Lundqvist E. Vulvar vestibulitis in the north of Sweden. An epidemiologic case–control study. J Reprod Med 1997;42:166–8.
33. Johannesson U, Sahlin L, Masironi B, Rylander E, Bohm-Starke N. Steroid receptor expression in the vulvar vestibular mucosa—effects of oral contraceptives and menstrual cycle. Contraception 2007;76:319–25.
34. Speroff L, Fritz MA. Hormone biosynthesis, metabolism and mechanism of action. In: Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005. p. 25–96.
35. Sant GR, Kempuraj D, Marchand JE, Theeoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007;69(suppl):34–40.
36. Kahn BS, Tatro C, Parsons CL, Willems JJ. Prevalence of interstitial cystitis in vulvodynia patients detected by bladder potassium sensitivity. J Sex Med 2010;7:996–1002.
37. Bjorling DE, Wang ZY. Estrogen and neuroinflammation. Urology 2001;57(suppl 1):40–6.
Figure. No caption available.